On July 3, 2023, I embarked on my final round (6) of treatment. The regiment mirrored rounds 4 and 5, involving a high dose of cytarabine administered every 12 hours for a total of 4 cycles. Once again, I found myself an inpatient at the Oncology/Hematology ward at UW Hospital in Madison, Wisconsin.
Before my admission, I underwent the customary blood tests and an office visit with Dr. Rajguru. These measures were crucial for assessing my body’s response to the prior treatment and preparing for the next. My platelet count was now 118. My other blood tests for white blood cells, red blood cells, and hemoglobin showed persisting abnormalities. The low hemoglobin levels were particularly evident in my daily activities, as even climbing a flight of stairs left me utterly exhausted.
Dr. Rajguru and I deliberated over my results, considering the possibility of further reducing the cytarabine dosage to 1000, down from the already adjusted 1500. Considering the success of round 5, I opted to maintain the 1500 dosage, aiming to maximize the potential benefits of the cytarabine while ensuring my body’s tolerance.
My hospitalization proceeded smoothly. The infusions of Rituximab and cytarabine continued without issue. The use of the iPad ultrasound device for IV placement was seamless. The hospital room felt familiar and routine. I even had the unexpected pleasure of watching the 4th of July fireworks over the lake from my hospital window. This final treatment cycle and hospital stay marked the culmination of an arduous journey, bringing a sense of relief and accomplishment.
Throughout my stay, I was pleasantly surprised by the variety and quality of the food provided. The chefs and delivery staff went above and beyond, ensuring there were plenty of options for three meals a day, along with snacks. This made my hospital experience more comfortable and helped me maintain my strength during treatment.